Qualigen Seeks Shareholder Nod for Private Placement, Equity Plan
Ticker: AIXC · Form: DEF 14A · Filed: Oct 20, 2025 · CIK: 1460702
Sentiment: mixed
Topics: Private Placement, Equity Incentive Plan, Stockholder Vote, Dilution Risk, Nasdaq Compliance, Biotechnology, Capital Raise
Related Tickers: AIXC
TL;DR
**AIXC needs this private placement and equity plan approved to stay afloat and incentivize its team, or it's dead money.**
AI Summary
Qualigen Therapeutics, Inc. (AIXC) is seeking stockholder approval for a private placement transaction from September 19, 2025, involving the issuance of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock. This offering is crucial for the company's financial health and future operations, requiring approval under Nasdaq Rule 5635(a) and (b). Additionally, AIXC needs approval for the potential issuance of common stock exceeding the 19.99% share exchange cap upon conversion of the Series B Preferred Stock, as per Nasdaq Rule 5635(d). The company is also proposing a new 2025 Equity Incentive Plan to align employee incentives with stockholder value. These proposals are being presented at a Special Meeting of Stockholders on November 12, 2025, with the Board of Directors unanimously recommending a 'FOR' vote on all four proposals. The record date for voting eligibility was September 22, 2025.
Why It Matters
This DEF 14A filing is critical for Qualigen Therapeutics as it outlines a significant capital raise through a private placement, which could provide essential funding for its drug development pipeline and operational expenses. For investors, approving the issuance of common stock and Series B Convertible Preferred Stock, potentially exceeding the 19.99% cap, could lead to dilution but also signals a lifeline for the company's strategic initiatives. The proposed 2025 Equity Incentive Plan is vital for attracting and retaining key talent in the highly competitive biotech sector, directly impacting the company's ability to execute its business plan and compete with larger pharmaceutical firms. Failure to approve these measures could severely hinder Qualigen's ability to secure necessary financing and incentivize its workforce, potentially jeopardizing its long-term viability and market position.
Risk Assessment
Risk Level: medium — The risk level is medium because while the private placement offers a potential capital infusion, the need for stockholder approval for exceeding the 19.99% share exchange cap (Proposal 2) suggests significant potential dilution for existing shareholders. Furthermore, the company is seeking approval for a new 2025 Equity Incentive Plan (Proposal 3), which, while common, could further dilute ownership if not managed carefully. The reliance on this private placement for funding indicates potential financial strain.
Analyst Insight
Investors should carefully evaluate the potential dilution from the private placement and the 2025 Equity Incentive Plan against the necessity of these measures for Qualigen's continued operations. Vote 'FOR' if you believe the capital infusion and incentive plan are essential for the company's survival and future growth, despite the dilution. Consider the long-term prospects of the company's pipeline.
Key Numbers
- 337,432 — Common Stock Shares (Shares of common stock to be issued in the private placement)
- 39,943 — Series B Preferred Stock Shares (Shares of Series B Convertible Preferred Stock to be issued in the private placement)
- 19.99% — Share Exchange Cap (Threshold for common stock issuance upon conversion of Series B Preferred Stock requiring approval)
- November 12, 2025 — Special Meeting Date (Date of the Special Meeting of Stockholders)
- September 22, 2025 — Record Date (Date for determining stockholders entitled to vote)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant seeking stockholder approval
- Nasdaq Rule 5635(a) and (b) (regulator) — Rule requiring approval for the private placement
- Nasdaq Rule 5635(d) (regulator) — Rule requiring approval for issuance exceeding 19.99% cap
- Kevin A. Richardson II (person) — Co-Chief Executive Officer of Qualigen Therapeutics, Inc.
- Jiawei Wang (person) — Proxyholder for voting on other business
- Securities and Exchange Commission (regulator) — Regulatory body for filing
- $337,432 (dollar_amount) — Shares of common stock to be issued in private placement
- $39,943 (dollar_amount) — Shares of Series B Convertible Preferred Stock to be issued in private placement
- Equiniti Trust Company, LLC (company) — Transfer agent for Qualigen Therapeutics, Inc.
FAQ
What is Qualigen Therapeutics asking stockholders to approve at the Special Meeting?
Qualigen Therapeutics is asking stockholders to approve four proposals: the private placement transactions from September 19, 2025, including the issuance of 337,432 common shares and 39,943 Series B Preferred shares; the issuance of common stock upon conversion of Series B Preferred Stock in excess of the 19.99% cap; the 2025 Equity Incentive Plan; and any adjournments or postponements of the meeting.
Why is Qualigen Therapeutics seeking approval for the private placement under Nasdaq rules?
Qualigen Therapeutics is seeking approval for the private placement under Nasdaq Rule 5635(a) and (b) because the transaction involves the issuance of a significant number of shares, specifically 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock, which requires stockholder consent to maintain listing compliance.
What is the significance of the 19.99% share exchange cap for Qualigen Therapeutics?
The 19.99% share exchange cap, governed by Nasdaq Rule 5635(d), is a threshold that, if exceeded by the issuance of common stock upon conversion of the Series B Convertible Preferred Stock, requires additional stockholder approval. This is significant as it addresses potential dilution for existing shareholders.
When is the Special Meeting of Stockholders for Qualigen Therapeutics?
The Special Meeting of Stockholders for Qualigen Therapeutics, Inc. will be held on November 12, 2025, at 10:00 AM local time, in a virtual-only format via internet at www.virtualshareholdermeeting.com/QLGN2025SM.
Who is eligible to vote at Qualigen Therapeutics' Special Meeting?
Only holders of record of Qualigen Therapeutics' Common Stock at the close of business on September 22, 2025, the Record Date, are entitled to notice of and to vote at the Special Meeting. Each stockholder is entitled to one vote for each share of Common Stock and Voting Preferred Stock held.
How does the Board of Directors recommend stockholders vote on the proposals for Qualigen Therapeutics?
The Board of Directors of Qualigen Therapeutics recommends that stockholders vote 'FOR' all four proposals: the Offering and Related Transactions Proposal, the Issuance Proposal, the 2025 Equity Incentive Plan Proposal, and the Adjournment Proposal.
What is the 2025 Equity Incentive Plan proposed by Qualigen Therapeutics?
The 2025 Equity Incentive Plan is a proposal by Qualigen Therapeutics to establish a new equity compensation plan. This plan is designed to incentivize employees and align their interests with those of stockholders, which is a common practice for companies to attract and retain talent.
What happens if stockholders do not approve the private placement for Qualigen Therapeutics?
If stockholders do not approve the private placement for Qualigen Therapeutics, the company may not be able to secure the necessary capital from the Subscription Agreement dated September 19, 2025. This could significantly impact its financial stability and ability to fund ongoing operations and development projects.
How can Qualigen Therapeutics stockholders vote if they hold shares in 'street name'?
If Qualigen Therapeutics stockholders hold shares in 'street name' through a broker, bank, or other nominee, they will receive instructions from their nominee on how to vote. They can typically deliver voting instructions over the internet, by telephone, or by completing and returning a voting instruction form.
Will broker non-votes affect the outcome of the proposals for Qualigen Therapeutics?
For Qualigen Therapeutics' Special Meeting, all four proposals (Offering, Issuance, 2025 Equity Incentive Plan, and Adjournment) are considered 'non-routine' matters. Therefore, broker non-votes will not affect the outcome of the vote on these proposals, as brokers are not permitted to vote on them without specific instructions from the beneficial owner.
Risk Factors
- Nasdaq Listing Rule Compliance [high — regulatory]: The company requires stockholder approval for the private placement and potential share issuance upon conversion of Series B Preferred Stock due to Nasdaq Rule 5635(a), (b), and (d). Failure to secure approval could jeopardize the company's Nasdaq listing.
- Reliance on Private Placement Financing [high — financial]: The company is seeking stockholder approval for a private placement involving 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock. This offering is described as crucial for the company's financial health and future operations, indicating a significant reliance on this capital infusion.
- Approval of 2025 Equity Incentive Plan [medium — operational]: The company is seeking stockholder approval for its 2025 Equity Incentive Plan. This plan is intended to align employee incentives with stockholder value, but its approval is necessary for the company's ability to grant equity-based compensation.
Industry Context
Qualigen Therapeutics operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on external financing, including private placements and equity offerings, to fund their operations and clinical trials. The competitive landscape is intense, with many companies vying for funding and market share in developing novel therapeutics.
Regulatory Implications
The company's reliance on Nasdaq listing rules (specifically Rule 5635) highlights the importance of shareholder approval for significant equity issuances. Failure to obtain these approvals could lead to delisting, severely impacting the company's liquidity and investor confidence. Compliance with these rules is paramount for maintaining market access.
What Investors Should Do
- Review the Proxy Statement carefully.
- Vote 'FOR' Proposals 1, 2, and 3.
- Submit your proxy or voting instructions promptly.
Key Dates
- 2025-11-12: Special Meeting of Stockholders — This is the date for the shareholder vote on critical proposals, including a private placement and an equity incentive plan.
- 2025-09-22: Record Date — Determines which stockholders are eligible to vote at the Special Meeting.
- 2025-09-19: Subscription Agreement Date — Date of the agreement for the private placement transaction requiring stockholder approval.
- 2025-10-20: Mailing of Proxy Materials — Indicates when stockholders will receive the necessary documents to review and vote on the proposals.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by a company to solicit shareholder votes. (This document outlines the proposals shareholders are being asked to vote on at the Special Meeting.)
- Private Placement
- A sale of securities directly to a small group of institutional or accredited investors, rather than through a public offering. (The company is seeking approval for a private placement of common and preferred stock, which is a key agenda item for the Special Meeting.)
- Series B Convertible Preferred Stock
- A class of preferred stock that can be converted into a specified number of shares of common stock. (The issuance and potential conversion of this stock are central to two of the proposals requiring shareholder approval.)
- Nasdaq Rule 5635
- Nasdaq listing rules that often require shareholder approval for certain equity issuances, such as those involving a significant percentage of outstanding shares or a change of control. (The company cites this rule as the basis for needing shareholder approval for the private placement and potential share issuances.)
- Share Exchange Cap
- A limit on the number of shares of common stock that can be issued upon the conversion of preferred stock, often expressed as a percentage of outstanding shares. (The company needs approval to issue shares exceeding this 19.99% cap upon conversion of the Series B Preferred Stock.)
- 2025 Equity Incentive Plan
- A plan established by a company to grant equity-based awards (like stock options or restricted stock) to employees, directors, or consultants. (Shareholder approval is sought for this plan, which is designed to incentivize and retain key personnel.)
Year-Over-Year Comparison
This filing is a proxy statement for a special meeting, not an annual report, and therefore does not provide comparative financial data from a prior year. The focus is on seeking shareholder approval for a private placement of 337,432 common shares and 39,943 Series B Convertible Preferred Shares, along with approval for the 2025 Equity Incentive Plan and potential share issuances exceeding Nasdaq's 19.99% cap. These actions indicate a current need for capital and a strategic move to incentivize employees, rather than a review of past performance.
Filing Stats: 4,679 words · 19 min read · ~16 pages · Grade level 13 · Accepted 2025-10-20 17:20:05
Key Financial Figures
- $41,000,000 — which the investors agreed to purchase $41,000,000 in cash (the “Offering”) of
- $0.001 — Company’s common stock, par value $0.001 per share (the “Common Stock&rdqu
- $2.246 — purchase price of the Common Stock was $2.246 per share and the purchase price for th
- $1,000 — rchase price for the Series B Stock was $1,000 per share (the “Stated Value&rdqu
- $6,800,000 — o;). The Company intends to use up to $6,800,000 of the net cash proceeds from the Offer
Filing Documents
- formdef14a.htm (DEF 14A) — 360KB
- prx_001.jpg (GRAPHIC) — 344KB
- prx_002.jpg (GRAPHIC) — 298KB
- 0001493152-25-018680.txt ( ) — 1246KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS 11 OTHER MATTERS 12 PROXY SOLICITATION AND COSTS 12 WHERE YOU CAN FIND MORE INFORMATION 12 i QUALIGEN THERAPEUTICS, INC. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 PROXY FOR SPECIAL MEETING OF STOCKHOLDERS TO BE HELD AT 10:00 A.M. PACIFIC TIME ON NOVEMBER 12, 2025 INTRODUCTION This Proxy Statement is being furnished in connection with the solicitation of proxies by our board of directors (the “Board”) for use at the Special Meeting of Stockholders (the “Special Meeting”) of Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and any postponements or adjournments thereof. The Special Meeting will be held on November 12, 2025. The information provided under “ Questions and Answers About These Proxy Materials and Voting ” below is for your convenience only. You should read this entire Proxy Statement carefully. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this Proxy Statement and references to our website address in this Proxy Statement are inactive textual references only. Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on November 12, 2025 We anticipate that this Proxy Statement, the Notice of Special Meeting of Stockholders, and the form of proxy card will be mailed to our stockholders commencing on or about October 20, 2025. We are using the “Full Set Delivery” method of providing proxy materials to stockholders. Because we have elected to utilize the “Full Set Delivery” option, we are delivering to all stockholders of record paper copies of this Proxy Statement and form of proxy card, as well as providing access to those proxy materials on a publicly accessible website. This Proxy Statement, form of proxy card, and the other Special Meetin